CRIS — CURIS INC

—
Nasdaq · Health Care · Biotechnology · CIK 1108205 ·
Last close
$0.54
Market Cap
$3.62M
52W High
$28.40
52W Low
$0.33
ADV30
8,400,622
Next earnings
2026-11-12
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 0 0 -9,940,000 -8,581,000 18,970,000 5,073,000 14,275,000
Mar 2026 0 0 -11,519,000 -24,199,000 29,686,000 15,001,000 16,979,000
Dec 2025 1,138,000 1,138,000 -7,570,000 19,356,000 19,966,000 5,061,000 14,504,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-30,587,000
Investing CF
$2,500,000
Financing CF
$23,022,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-14.22
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,280,161,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-8,448,000
Pretax Income TTM
$-21,153,000
Interest Exp TTM
—
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$4,314,000
EBITDA
$-35,869,000
Free Cash Flow
$-15,766,000
Enterprise Value
$-2,833,894
Total Cash
$5,073,000
Total Debt
$1,044,000
Shares Out
6,679,229
Trailing EPS
$1.32
Book Value
$8.45
ROE
-693.9%
ROA
-93.2%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 9,443,000 -32,902,000 -7,582,000 19,966,000 14,504,000 5,462,000 -27,201,000
Dec 2024 10,908,000 -44,542,000 -43,389,000 41,265,000 47,263,000 -5,998,000 -39,563,000
Dec 2023 10,023,000 -48,332,000 -47,413,000 77,282,000 57,612,000 19,670,000 -38,434,000
Dec 2022 10,162,000 -53,020,000 -56,672,000 108,848,000 62,296,000 46,552,000 -54,337,000

TTM Snapshot

Revenues TTM
$4,314,000
NetIncome TTM
$-21,153,000
OpCashFlow TTM
—
Assets (Latest)
$18,970,000
Forward EPS
$-5.60

Peers — same industry

TickerNameMarket CapLastDaily %
CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. $3.62M $0.48 —
LIMN Liminatus Pharma, Inc. $3.77M $2.81 —
SNTI Senti Biosciences Holdings, Inc. $3.02M $0.10 —
BCAB BioAtla, Inc. $3.00M $1.80 —
SCLX Scilex Holding Co $4.52M $0.64 —

News headlines (Yahoo Finance, 1h cache)

Curis (CRIS) Stock Fair Value Falls After Q3 And Private Placement Rework
2026-11-18 17:13 · Yahoo
Curis, Inc. Q3 2026 Earnings Call Summary
2026-11-13 13:30 · Yahoo
Curis (CRIS) Q3 2026 Earnings Call Transcript
2026-11-13 07:13 · Yahoo
Curis: Q3 Earnings Snapshot
2026-11-12 21:07 · Yahoo
Curis Provides Third Quarter 2026 Business Update
2026-11-12 21:01 · Yahoo
Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026
2026-11-05 21:30 · Yahoo
BC-Most Active Stocks
2026-11-04 15:30 · Yahoo
Curis Shares Surge 70.7% as Reverse Stock Split Vote and Upcoming Clinical Data Attract Investors
2026-11-04 13:42 · Yahoo
Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors
2026-10-16 12:00 · Yahoo
VISTA Inhibitor Market Insights Report 2026 | Featuring Profiles of Aurigene Discovery Technologies, Curis, Hummingbird Bioscience, Kineta, PharmAbcine
2026-08-26 14:16 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.